AMGEN®

DOWNLOAD PIPELINE CHART

PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

FILTER (0)

abp 206

Showing 1 result abp 206

Clear Search

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
ABP 206 (Investigational biosimilar to OPDIVO® (nivolumab))	Hematology / Oncology	Investigational Biosimilar	Monoclonal Antibody	3

DESCRIPTION

ABP 206 is an investigational biosimilar to OPDIVO (nivolumab), which is a monoclonal antibody that binds to the receptor protein called programmed death protein 1 (PD-1).

ADDITIONAL INFORMATION

OPDIVO is a registered trademark of Bristol-Myers Squibb Company.

Amgen.com

AmgenScience.com

Amgentrials.com

* Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

** Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 1, 2025, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN®

Terms of Use Privacy Statement Consumer Health Data Privacy Policy Your Cookie Preferences

© 2024 Amgen Inc. All Rights Reserved.